
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
Santa Barbara, CA-Bausch & Lomb will review results of Miravant Medical Technologies' SnET2 trials with an option to negotiate the exclusive worldwide license to develop and commercialize the drug for the treatment of wet age-related macular degeneration (AMD).




